莱西康制药 LXRX
$1.78 +$0.17 (+10.56%)
休市 · Nov 6, 8:20 pm ET · 最新盘后价 $1.78 0.00%
开盘$1.66
昨收$1.61
当日区间$1.61 – $1.84
成交量3.60M
市值$792.52M
市盈率（TTM）–
股息率–
LXRX 相关新闻
匹配 Lexicon Pharmaceuticals 或代码 LXRX 的头条新闻，按最新排序。
- Cantor Fitzgerald Initiates Lexicon Pharmaceuticals(LXRX.US) With Buy Rating, Announces Target Price $8
- Cantor Fitzgerald Initiates Coverage On Lexicon Pharmaceuticals With Overweight Rating, Announces Price Target of $8
- Cantor Fitzgerald Initiates Lexicon Pharmaceuticals at Overweight With $8 Price Target
- Citi Maintains Lexicon Pharmaceuticals(LXRX.US) With Buy Rating, Maintains Target Price $3.1
- Piper Sandler Maintains Lexicon Pharmaceuticals(LXRX.US) With Buy Rating, Maintains Target Price $6
- 10-Q: Lexicon Pharmaceuticals | 10-Q: Q2 2026 Earnings Report
- Lexicon Pharmaceuticals | S-3: Registration statement for specified transactions by certain issuers
- S-8: Lexicon Pharmaceuticals | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
- Analysts Conflicted on These Healthcare Names: Lexicon Pharmaceuticals (LXRX), Ascendis Pharma (ASND) and Lantheus (LNTH)
- Earnings Flash (LXRX) Lexicon Pharmaceuticals Posts Q2 Loss $0.07 a Share, Vs. FactSet Est of $0.05 Loss 负面
- SCHEDULE 13G/A: Lexicon Pharmaceuticals | SCHEDULE 13G/A: Others
- Analysts Have Conflicting Sentiments on These Healthcare Companies: Lexicon Pharmaceuticals (LXRX) and MaxCyte (MXCT)
- H.C. Wainwright Maintains Lexicon Pharmaceuticals(LXRX.US) With Buy Rating, Maintains Target Price $6
- Lexicon Pharmaceuticals | EFFECT: Others
- Lexicon Pharmaceuticals: Advancing Cardiometabolic Pipeline and Phase 3 HCM Data Support Unchanged $6 Price Target and Buy Rating
暂无评论——快来第一个聊聊 LXRX。
登录后参与讨论。